Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Vernalis plc    VER   GB00B3Y5L754

Delayed Quote. Delayed  - 02/09 11:35:10 am
54.5 GBp   -3.96%
02/04 VERNALIS : "Vernalis" or the "Company") Notice of Results for the Si..
01/09 VERNALIS : Announces Adenosine Antagonist Licensee
01/06 VERNALIS : Reveals US-Based Corvus Pharmaceuticals As Licensee
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
02/03/2016 02/04/2016 02/05/2016 02/08/2016 02/09/2016 Date
57.25(c) 56(c) 56(c) 56.75(c) 54.5(c) Last
42 723 2 055 38 129 8 594 29 899 Volume
-0.43% -2.18% 0.00% +1.34% -3.96% Change
More quotes
Financials ( GBP)
Sales 2016 16,1 M
EBIT 2016 -27,0 M
Net income 2016 -26,0 M
Finance 2016 5,86 M
Yield 2016 -
Sales 2017 36,0 M
EBIT 2017 -12,8 M
Net income 2017 -11,9 M
Debt 2017 0,59 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 15,3x
EV / Sales 2017 7,03x
Capitalization 253 M
More Financials
Company
Vernalis Plc is a research and development stage pharmaceutical company.The company provides pharmaceutical products for a range of medical disorders.It focuses on de novo fragment and structure based drug discovery and pre clinical and clinical development.The group has one marketed product,... 
Sector
Biotechnology & Medical Research
Calendar
03/17 | 02:00amEarnings Release
More about the company
Surperformance© ratings of Vernalis plc
Trading Rating : Investor Rating :
More Ratings
Latest news on VERNALIS PLC
02/04 VERNALIS : "Vernalis" or the "Company") Notice of Results for the Six Months End..
01/09 VERNALIS : Announces Adenosine Antagonist Licensee
01/06 VERNALIS : Reveals US-Based Corvus Pharmaceuticals As Licensee
01/06 VERNALIS : Announces Adenosine Antagonist Licensee
01/06 VERNALIS : Announces Corvus Pharmaceuticals, Inc. as Its Worldwide Licensee for ..
2015 VERNALIS : Says Cough Cold Drug CCP-07 Completes Single-Dose Study
2015 VERNALIS : Announce CCP-07 Single-Dose Study Results
2015 VERNALIS : Announces Successful Completion of CCP-07 Pivotal Single-Dose Compara..
More news
Sector news : Biotechnology & Medical Research - NEC
06:02pDJPanel Recommends FDA Approval of Remicade Knockoff
05:07p JOHNSON & JOHNSON : FDA panel backs lower-cost version of J&J's top-selling drug
09:22aDJU.S. HOT STOCKS : Hot Stocks to Watch
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
2015 Vernalis acquires U.S. rights to extended-release antibiotic


Comments 
Advertisement
Chart VERNALIS PLC
Duration : Period :
Vernalis plc Technical Analysis Chart | VER | GB00B3Y5L754 | 4-Traders
Full-screen chart
Technical analysis trends VERNALIS PLC
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions